Impact of hepatitis virus and aging on DNA methylation in human hepatocarcinogenesis

Histology and Histopathology

Volumn 25, Issue 5, 2010, Pages 647-654

  Nishida, Naoshi ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Aging; DNA methylation; Hepatitis virus; Hepatocellular carcinoma; Tumor suppressor gene

Indexed keywords

HEPATITIS C VIRUS;

AGING; BIOLOGICAL MODEL; DNA METHYLATION; GENETIC EPIGENESIS; GENETICS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; PATHOGENICITY; PROMOTER REGION; REVIEW; TUMOR SUPPRESSOR GENE;

AGING; CARCINOMA, HEPATOCELLULAR; DNA METHYLATION; EPIGENESIS, GENETIC; GENES, TUMOR SUPPRESSOR; HEPACIVIRUS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER NEOPLASMS; MODELS, BIOLOGICAL; PROMOTER REGIONS, GENETIC;

EID: 77953066813     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Barton A.L., Banner B.F., Cable E.E. and Bonkovsky H.L. (1995). Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy. Am. J. Clin. Pathol. 103, 419-424.
2. Ding S., Gong B.D., Yu J., Gu J., Zhang H.Y., Shang Z.B., Fei Q., Wang P. and Zhu J.D. (2004). Methylation profile of the promoter CpG islands of 14 "drug-resistance" genes in hepatocellular carcinoma. World J. Gastroenterol. 10, 3433-3440. (Pubitemid 39549543)
3. Harder J., Opitz O.G., Brabender J., Olschewski M., Blum H.E., Nomoto S. and Usadel H. (2008). Quantitative promoter methylation analysis of hepatocellular carcinoma, cirrhotic and normal liver. Int. J. Cancer 122, 2800-2804.
4. Iwata N., Yamamoto H., Sasaki S., Itoh F., Suzuki H., Kikuchi T., Kaneto H., Iku S., Ozeki I., Karino Y., Satoh T., Toyota J., Satoh M., Endo T. and Imai K. (2000). Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma. Oncogene 19, 5298-5302.
5. Jicai Z., Zongtao Y., Jun L., Haiping L., Jianmin W. and Lihua H. (2006). Persistent infection of hepatitis B virus is involved in high rate of p16 methylation in hepatocellular carcinoma. Mol. Carcinog. 45, 530-536.
6. Jung J.K., Arora P., Pagano J.S. and Jang K.L. (2007). Expression of DNA methyltransferase 1 is activated by hepatitis B virus X protein via a regulatory circuit involving the p16INK4a-cyclin D1-CDK 4/6-pRb-E2F1 pathway, Cancer Res. 67. 5771-5778.
7. Kanai Y., Ushijima S., Hui A. M., Ochiai A., Tsuda H., Sakamoto M. and Hirohashi S. (1997). The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas. Int. J. Cancer 71, 355-359.
8. Kaneto H., Sasaki S., Yamamoto H., Itoh F., Toyota M., Suzuki H., Ozeki I., Iwata N., Ohmura T., Satoh T., Karino Y., Toyota J., Satoh M., Endo T., Omata M. and Imai K. (2001). Detection of hypermethylation of the p16(INK4A) gene promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C virus. Gut 48, 372-377.
9. Kato J., Kobune M., Nakamura T., Kuroiwa G., Takada K., Takimoto R., Sato Y., Fujikawa K., Takahashi M., Takayama T., Ikeda T. and Niitsu Y. (2001). Normalization of elevated hepatic 8-hydroxy-2′-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Res. 61, 8697-8702.
10. Kim M.J., White-Cross J.A., Shen L., Issa J.P. and Rashid A. (2009). Hypomethylation of long interspersed nuclear element-1 in hepatocellular carcinomas. Mod. Pathol. 22, 442-449.
11. Ko E., Kim S.J., Joh J.W., Park C.K., Park J. and Kim D.H. (2008). CpG island hypermethylation of SOCS-1 gene is inversely associated with HBV infection in hepatocellular carcinoma. Cancer Lett. 271, 240-250.
12. Kondo Y., Kanai Y., Sakamoto M., Mizokami M., Ueda R. and Hirohashi S. (2000). Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis-A comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma. Hepatology 32, 970-979.
13. Lee H.S., Kim B.H., Cho N.Y., Yoo E.J., Choi M., Shin S.H., Jang J.J., Suh K.S., Kim Y.S. and Kang G.H. (2009). Prognostic implications of and relationship between CpG island hypermethylation and repetitive DNA hypomethylation in hepatocellular carcinoma. Clin. Cancer Res. 15, 812-820.
14. Lee J.O., Kwun H.J., Jung J.K., Choi K.H., Min D.S. and Jang K.L. (2005). Hepatitis B virus X protein represses E-cadherin expression via activation of DNA methyltransferase 1. Oncogene 24, 6617-6625.
15. Lee S., Lee H.J., Kim J.H., Lee H.S., Jang J.J. and Kang G.H. (2003). Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am. J. Pathol. 163, 1371-1378. (Pubitemid 37175085)
16. Lehmann U., Berg-Ribbe I., Wingen L.U., Brakensiek K., Becker T., Klempnauer J., Schlegelberger B., Kreipe H. and Flemming P. (2005). Distinct methylation patterns of benign and malignant liver tumors revealed by quantitative methylation profiling. Clin. Cancer Res. 11, 3654-3660.
17. Lehmann U., Wingen L.U., Brakensiek K., Wedemeyer H., Becker T., Heim A., Metzig K., Hasemeier B., Kreipe H. and Flemming P. (2007). Epigenetic defects of hepatocellular carcinoma are already found in non-neoplastic liver cells from patients with hereditary haemochromatosis. Hum. Mol. Genet. 16, 1335-1342.
18. Li H.P., Leu Y.W. and Chang Y.S. (2005). Epigenetic changes in virus-associated human cancers. Cell Res. 15, 262-271.
19. Li X., Hui A.M., Sun L., Hasegawa K., Torzilli G., Minagawa M., Takayama T. and Makuuchi M. (2004). p16INK4A hypermethylation is associated with hepatitis virus infection, age, and gender in hepatocellular carcinoma. Clin. Cancer Res. 10, 7484-7489.
20. Lim S.O., Gu J.M., Kim M.S., Kim H.S., Park Y.N., Park C.K., Cho J.W., Park Y.M. and Jung G. (2008). Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter. Gastroenterology 135, 2128-2140.
21. Loft S. and Poulsen H.E. (1996). Cancer risk and oxidative DNA damage in man. J. Mol. Med. 74, 297-312.
22. Macheiner D., Heller G., Kappel S., Bichler C., Stattner S., Ziegler B., Kandioler D., Wrba F., Schulte-Hermann R., Zochbauer-Muller S. and Grasl-Kraupp B. (2006). NORE1B, a candidate tumor suppressor, is epigenetically silenced in human hepatocellular carcinoma. J. Hepatol. 45, 81-89.
23. Matsumoto K., Satoh Y., Sugo H., Takamori S., Kojima K., Fukasawa M., Beppu T. and Futagawa S. (2003). Immunohistochemical study of the relationship between 8-hydroxy-2′-deoxyguanosine levels in noncancerous region and postoperative recurrence of hepatocellular carcinoma in remnant liver. Hepatol. Res. 25, 435-441.
24. Mindikoglu A.L. and Miller R.R. (2009). Hepatitis C in the elderly: epidemiology, natural history, and treatment. Clin. Gastroenterol. Hepatol. 7, 128-134.
25. Nishida N., Fukuda Y., Kokuryu H., Sadamoto T., Isowa G., Honda K., Yamaoka Y., Ikenaga M., Imura H. and Ishizaki K. (1992). Accumulation of allelic loss on arms of chromosomes 13q, 16q and 17p in the advanced stages of human hepatocellular carcinoma. Int. J. Cancer 51, 862-868.
26. Nishida N., Fukuda Y., Kokuryu H., Toguchida J., Yandell D.W., Ikenaga M., Imura H. and Ishizaki K. (1993). Role and mutational heterogeneity of the p53 gene in hepatocellular carcinoma. Cancer Res. 53, 368-372.
27. Nishida N., Fukuda Y., Komeda T., Kita R., Sando T., Furukawa M., Amenomori M., Shibagaki I., Nakao K., Ikenaga M. and Ishizaki K. (1994). Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res. 54, 3107-3110.
28. Nishida N., Nishimura T., Ito T., Komeda T., Fukuda Y. and Nakao K. (2003). Chromosomal instability and human hepatocarcinogenesis. Histol. Histopathol. 18, 897-909.
29. Nishida N., Nishimura T., Nagasaka T., Ikai I., Goel A. and Boland C.R. (2007). Extensive methylation is associated with beta-catenin mutations in hepatocellular carcinoma: evidence for two distinct pathways of human hepatocarcinogenesis. Cancer Res. 67, 4586-4594.
30. Nishida N., Nagasaka T., Nishimura T., Ikai I., Boland C.R. and Goel A. (2008). Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology 47, 908-918.
31. Niwa Y., Kanda H., Shikauchi Y., Saiura A., Matsubara K., Kitagawa T., Yamamoto J., Kubo T. and Yoshikawa H. (2005). Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene 24, 6406-6417.
32. Park H.J., Yu E. and Shim Y.H. (2006). DNA methyltransferase expression and DNA hypermethylation in human hepatocellular carcinoma. Cancer Lett. 233, 271-278.
33. Park I.Y., Sohn B.H., Yu E., Suh D.J., Chung Y.H., Lee J.H., Surzycki S.J. and Lee Y.I. (2007). Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein. Gastroenterology 132, 1476-1494.
34. Qiu W., Zhou B., Zou H., Liu X., Chu P.G., Lopez R., Shih J., Chung C. and Yen Y. (2004). Hypermethylation of growth arrest DNA damage-inducible gene 45 beta promoter in human hepatocellular carcinoma. Am. J. Pathol. 165, 1689-1699.
35. Saito Y., Kanai Y., Sakamoto M., Saito H., Ishii H. and Hirohashi S. (2001). Expression of mRNA for DNA methyltransferases and methyl-CpG-binding proteins and DNA methylation status on CpG islands and pericentromeric satellite regions during human hepatocarcinogenesis. Hepatology 33, 561-568.
36. Saito Y., Kanai Y., Sakamoto M., Saito H., Ishii H. and Hirohashi S. (2002). Overexpression of a splice variant of DNA methyltransferase 3b, DNMT3b4, associated with DNA hypomethylation on pericentromeric satellite regions during human hepato-carcinogenesis. Proc. Natl. Acad. Sci. USA 99, 10060-10065.
37. Sakai M., Hibi K., Kanazumi N., Nomoto S., Inoue S., Takeda S. and Nakao A. (2005). Aberrant methylation of the CHFR gene in advanced hepatocellular carcinoma. Hepatogastroenterology 52, 1854-1857.
38. Saneto H., Kobayashi M., Kawamura Y., Yatsuji H., Sezaki H., Hosaka T., Akuta N., Suzuki F., Suzuki Y., Arase Y., Ikeda K. and Kumada H. (2008). Clinicopathological features, background liver disease, and survival analysis of HCV-positive patients with hepatocellular carcinoma: differences between young and elderly patients. J. Gastroenterol. 43, 975-981.
39. Shen L., Ahuja N., Shen Y., Habib N.A., Toyota M., Rashid A. and Issa J.P. (2002). DNA methylation and environmental exposures in human hepatocellular carcinoma. J. Natl. Cancer Inst. 94, 755-761.
40. Shih Y.L., Shyu R.Y., Hsieh C.B., Lai H.C., Liu K.Y., Chu T.Y. and Lin Y.W. (2006). Promoter methylation of the secreted frizzled-related protein 1 gene SFRP1 is frequent in hepatocellular carcinoma. Cancer 107, 579-590.
41. Shim Y.H., Yoon G.S., Choi H.J., Chung Y.H. and Yu E. (2003). p16 Hypermethylation in the early stage of hepatitis B virus-associated hepatocarcinogenesis. Cancer Lett. 190, 213-219.
42. Su P.F., Lee T.C., Lin P.J., Lee P.H., Jeng Y.M., Chen C.H., Liang J.D., Chiou L.L., Huang G.T. and Lee H.S. (2007). Differential DNA methylation associated with hepatitis B virus infection in hepatocellular carcinoma. Int. J. Cancer 121, 1257-1264.
43. Tada M., Yokosuka O., Fukai K., Chiba T., Imazeki F., Tokuhisa T. and Saisho H. (2005). Hypermethylation of NAD(P)H: quinone oxidoreductase 1 (NQO1) gene in human hepatocellular carcinoma. J. Hepatol. 42, 511-519.
44. Thorgeirsson S.S. and Grisham J.W. (2002). Molecular pathogenesis of human hepatocellular carcinoma. Nat. Genet. 31, 339-346.
45. Tischoff I., Markwarth A., Witzigmann H., Uhlmann D., Hauss J., Mirmohammadsadegh A., Wittekind C., Hengge U.R. and Tannapfel A. (2005). Allele loss and epigenetic inactivation of 3p21.3 in malignant liver tumors. Int. J. Cancer 115, 684-689.
46. Valinluck V. and Sowers L.C. (2007a). Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1. Cancer Res. 67, 946-950.
47. Valinluck V. and Sowers L.C. (2007b). Inflammation-mediated cytosine damage: a mechanistic link between inflammation and the epigenetic alterations in human cancers. Cancer Res. 67, 5583-5586.
48. Wong I.H., Lo Y.M., Zhang J., Liew C.T., Ng M.H., Wong N., Lai P.B., Lau W.Y., Hjelm N.M. and Johnson P.J. (1999). Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res. 59, 71-73.
49. Xiao W.H. and Liu W.W. (2004). Hemizygous deletion and hypermethylation of RUNX3 gene in hepatocellular carcinoma. World J. Gastroenterol. 10, 376-380.
50. Yang B., Guo M., Herman J.G. and Clark D.P. (2003). Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am. J. Pathol. 163, 1101-1107.
51. Yau T.O., Chan C.Y., Chan K.L., Lee M.F., Wong C.M., Fan S.T. and Ng I.O. (2005). HDPR1, a novel inhibitor of the WNT/beta-catenin signaling, is frequently downregulated in hepatocellular carcinoma: involvement of methylation-mediated gene silencing. Oncogene 24, 1607-1614.
52. Yoshida H., Shiratori Y., Moriyama M., Arakawa Y., Ide T., Sata M., Inoue O., Yano M., Tanaka M., Fujiyama S., Nishiguchi S., Kuroki T., Imazeki F., Yokosuka O., Kinoyama S., Yamada G. and Omata M. (1999). Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann. Intern. Med. 131, 174-181.
53. Yoshikawa H., Matsubara K., Qian G.S., Jackson P., Groopman J.D., Manning J.E., Harris C.C. and Herman J.G. (2001). SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat. Genet. 28, 29-35.
54. Yu J., Ni M., Xu J., Zhang H., Gao B., Gu J., Chen J., Zhang L., Wu M., Zhen S. and Zhu J. (2002). Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis. BMC Cancer 2, 29.
55. Yuan Y., Wang J., Li, J., Wang L., Li M., Yang Z., Zhang C. and Dai J L. (2006). Frequent epigenetic inactivation of spleen tyrosine kinase gene in human hepatocellular carcinoma. Clin. Cancer Res. 12, 6687-6695.
56. Zhang Y.J., Ahsan H., Chen Y., Lunn R.M., Wang L.Y., Chen S.Y., Lee P.H., Chen C.J. and Santella R.M. (2002). High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma. Mol. Carcinog. 35, 85-92.
57. Zhang Y.J., Wu H.C., Shen J., Ahsan H., Tsai W.Y., Yang H.I., Wang L.Y., Chen S.Y., Chen C.J. and Santella R.M. (2007). Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin. Cancer Res. 13, 2378-2384.
58. Zheng D.L., Zhang L., Cheng N., Xu X., Deng Q., Teng X.M., Wang K.S., Zhang X., Huang J. and Han Z.G. (2009). Epigenetic modification induced by hepatitis B virus X protein via interaction with de novo DNA methyltransferase DNMT3A. J. Hepatol. 50, 377-387.
59. Zhong S., Tang M.W., Yeo W., Liu C., Lo Y.M. and Johnson P.J. (2002). Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinomas. Clin. Cancer Res. 8, 1087-1092.
60. Zhong S., Yeo W., Tang M.W., Wong N., Lai P.B. and Johnson P.J. (2003). Intensive hypermethylation of the CpG island of Ras association domain family 1A in hepatitis B virus-associated hepatocellular carcinomas. Clin. Cancer Res. 9, 3376-3382.
61. Zhu R., Li B.Z., Li H., Ling Y.Q., Hu X.Q., Zhai W.R. and Zhu H.G. (2007). Association of p16INK4A hypermethylation with hepatitis B virus X protein expression in the early stage of HBV-associated hepatocarcinogenesis. Pathol. Int. 57, 328-336.